Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Vertex Pharmaceuticals (VRTX - Snapshot Report) recently presented promising data on its influenza candidate, VX-787. The company presented results from a double-blind, randomized, placebo-controlled phase IIa study.

Treatment with VX-787 led to a statistically significant improvement in viral and clinical measurements of infection. VX-787 achieved the primary endpoint of the study and demonstrated a statistically significant decline in the amount of virus in nasal secretions during the seven-day study period.

Moreover, a statistically significant reduction in the severity and duration of influenza-like symptoms was observed at the highest dosing regimen. Patients in this dosing arm suffered from influenza-like symptoms for a median of 1.9 days compared to 3.7 days for the placebo arm.

After three days of treatment, 93% of patients in the highest dosing regimen arm showed no clinical symptoms of influenza compared to 41% in the placebo arm.

Vertex Pharma said that VX-787 was found to be generally well-tolerated with no discontinuations being reported.

With these encouraging results in hand, Vertex Pharma intends to seek partnership deals to support the development of the candidate.

Our Take

We are encouraged by the promising data presented by Vertex Pharma on VX-787. We believe the results will help the company secure a lucrative partnership deal for the candidate.

The influenza market holds huge commercial potential. VX-787 represents a new class of potential treatment for influenza and its differentiated mechanism of action compared to currently approved treatments could help it gain share once launched. Rapid onset of action and an expanded treatment window could work in VX-787’s favor.

Vertex Pharma currently carries a Zacks Rank #3 (Hold). Companies that currently look more attractive include Cytokinetics, Inc. (CYTK - Snapshot Report), Array BioPharma (ARRY - Snapshot Report) and Agenus, Inc. (AGEN - Snapshot Report). While Cytokinetics is a Zacks Rank #1 (Strong Buy) stock, both Array BioPharma and Agenus are Zacks Rank #2 (Buy) stocks.

 

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%